Leadership Overview
Synokem Pharmaceuticals has 5 executives leading key functions including strategy, international business, and operations.
Driven by a commitment to affordable healthcare, Synokem Pharmaceuticals aims to be a world-class manufacturer, enhancing its market share through strategic alliances and a strong focus on research and development to achieve significant growth.
Driven by a commitment to affordable healthcare, Synokem Pharmaceuticals aims to be a world-class manufacturer, enhancing its market share through strategic alliances and a strong focus on research and development to achieve significant growth.
Leadership Roles at Synokem Pharmaceuticals
Rajat Adhikari - President
Rajat Adhikari, the President at Synokem Pharmaceuticals, directs the overarching strategic vision and operational framework for the organization. This leadership role involves guiding the company's expansion efforts, particularly in enhancing its market share through strategic alliances and collaborations, aligning with the goal of becoming a world-class manufacturer. Adhikari oversees the integration of research and development initiatives, ensuring they support the company's commitment to providing affordable, quality pharmaceutical products. The President's responsibilities extend to fostering an environment conducive to significant growth and establishing Synokem Pharmaceuticals as an industry leader. Rajat Adhikari ensures that all departmental functions operate in synergy to meet the company's mission of making pharmaceuticals accessible to all societal segments. This involves close coordination with other executive functions to drive innovation and maintain competitive positioning in both domestic and international markets.
Pankaj Synokempharma - President - Exports
Pankaj Synokempharma, the President - Exports at Synokem Pharmaceuticals, spearheads the company's international business development and global market penetration strategies. This critical role focuses on expanding Synokem's reach through ethical marketing, exports, and institutional supplies to diverse global markets. Synokempharma is responsible for identifying and cultivating strategic alliances and collaborations abroad, directly contributing to the company's vision of becoming a world-class manufacturer with a significant international footprint. The President - Exports oversees the logistical and regulatory navigation required for successful global trade, ensuring compliance and maximizing market opportunities. Pankaj Synokempharma drives the company's export revenue streams, working to make quality pharmaceutical products affordable across different societies worldwide. This executive's efforts are central to Synokem's ambition for substantial growth and establishing a robust presence in the international pharmaceutical sector.
Surender Arora - President
Surender Arora, the President at Synokem Pharmaceuticals, manages the operational execution and efficiency of the company's diverse business segments, including contract manufacturing and ethical marketing. This leadership position ensures the seamless delivery of quality pharmaceutical products, reinforcing Synokem's commitment to affordability and accessibility across society. Arora oversees the internal processes that support the company's vision of becoming a world-class manufacturer, focusing on optimizing production capabilities and supply chain management. The President's role involves driving operational excellence to enhance market share, particularly through reliable contract manufacturing services and effective ethical marketing campaigns. Surender Arora champions the company's dedication to research and development by ensuring that operational resources are aligned with innovation goals. This executive's focus on robust execution is fundamental to Synokem Pharmaceuticals' sustained growth and its establishment as a trusted industry leader.
Rajan Mahendru - President
Rajan Mahendru, the President at Synokem Pharmaceuticals, directs the company's institutional supplies and ethical marketing initiatives, ensuring broad access to affordable, quality pharmaceutical products. This executive is pivotal in strengthening Synokem's market presence by managing relationships with institutional clients and overseeing the strategic deployment of ethical marketing efforts. Mahendru's leadership supports the company's objective to become a world-class manufacturer by ensuring consistent product availability and effective market outreach. The President's responsibilities include driving growth through enhanced distribution channels and reinforcing the company's commitment to societal well-being by making essential medicines accessible. Rajan Mahendru collaborates with other executive leaders to foster strategic alliances and collaborations that amplify Synokem Pharmaceuticals' market share. This executive's focus on operational reach and market engagement is key to the company's ongoing development and industry leadership aspirations.
Sandeep Soni - President
Sandeep Soni, the President at Synokem Pharmaceuticals, drives the company's strategic initiatives in research and development, aiming to foster innovation and achieve significant growth. This leadership role is central to Synokem's vision of becoming a world-class manufacturer by advancing the development of new pharmaceutical products and improving existing formulations. Soni oversees the integration of cutting-edge research with the company's commitment to providing affordable, quality medicines, ensuring that scientific advancements translate into societal benefits. The President's focus on R&D is critical for enhancing market share through differentiated offerings and establishing Synokem Pharmaceuticals as an industry leader in innovation. Sandeep Soni works to cultivate strategic alliances and collaborations that accelerate research pipelines and expand the company's technological capabilities. This executive's dedication to scientific progress underpins Synokem's long-term growth trajectory and its mission to make healthcare accessible globally.
Explore Leadership Teams in Manufacturing
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novartis maintains a significant presence in scientific research, with extensive operations spanning across Europe, North America, Asia, and other global regions.
Company Leadership WV
DC
PD
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Company Leadership
JM
LJ
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
诺诚健华 is focused on developing innovative drugs to address significant unmet clinical needs in the fields of malignant tumors and autoimmune diseases. The company possesses comprehensive research and commercialization capabilities, aiming to create first-in-class or best-in-class therapies for global markets. With a strong pipeline in hematological malignancies, autoimmune diseases, and solid tumors, 诺诚健华 is committed to delivering high-quality innovative medicines that benefit patients worldwide. The company is led by co-founder and CEO Dr. 崔霁松, who emphasizes the importance of scientific-driven innovation.
Company Leadership NB
KG
SZ
Frequently Asked Questions Regarding Synokem Pharmaceuticals Top Executives and Leadership Team
